Fetal origins of adult disease: a paediatric perspective

Harriet L Miles1, Paul L Hofman, Wayne S Cutfield

  • 1Liggins Institute, University of Auckland, Private Bag 92019, New Zealand.

Insights

Children born small for gestational age (SGA) or very low birth weight (VLBW) show insulin resistance. Early life environment significantly impacts growth and metabolic axes, influencing long-term health outcomes.

Area of Science:

  • Pediatric Endocrinology
  • Developmental Biology
  • Metabolic Health

Background:

  • Children born small for gestational age (SGA) or very low birth weight (VLBW) often experience suboptimal intrauterine environments, leading to short stature.
  • These growth disparities are associated with distinct alterations in the growth hormone (GH) and insulin-like growth factor (IGF) axes.

Purpose of the Study:

  • To investigate the differing endocrine and metabolic consequences of SGA and VLBW in prepubertal children.
  • To explore the impact of early life environmental insults on growth and metabolic programming.

Main Methods:

  • Comparative analysis of SGA and VLBW children's growth parameters.
  • Assessment of the growth hormone (GH) and IGF-I axis in relation to metabolic status.
  • Examination of endocrine profiles in children conceived via in vitro fertilization (IVF).

Main Results:

  • SGA children exhibited elevated IGF-I levels, suggesting hyperinsulinism or partial IGF-I resistance.
  • VLBW children displayed low IGF-I and IGFBP-3 levels, indicative of GH resistance.
  • IVF children were taller with increased IGF-I, IGF-II, and IGFBP-3, potentially due to periconceptual environmental effects on gene imprinting.

Conclusions:

  • The timing and nature of early life environmental insults differentially affect metabolic and endocrine axes.
  • Environmental factors during critical developmental periods can program long-term phenotypic, endocrine, and metabolic outcomes.
  • Further research is needed to elucidate the mechanisms linking environmental changes to programmed effects on growth and metabolism.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...